Equity of access to pathological diagnosis and bronchoscopy for lung cancer in Aotearoa New Zealand

被引:0
|
作者
Gurney, Jason [1 ]
Davies, Anna [1 ]
Stanley, James [1 ]
Whitehead, Jesse [2 ]
Cameron, Laird [3 ]
Costello, Shaun [4 ]
Dawkins, Paul [5 ]
Koea, Jonathan [6 ]
机构
[1] Univ Otago, Dept Publ Hlth, 23a Mein St, Wellington 6037, New Zealand
[2] Univ Waikato, Te Ngira Inst Populat Res, Hamilton, New Zealand
[3] Te Whatu Ora Te Toka Tumai Auckland, Auckland, New Zealand
[4] Te Whatu Ora Southern, Southern Blood & Canc Unit, Dunedin, New Zealand
[5] Te Whatu Ora Cty Manukau, Resp Serv, Auckland, New Zealand
[6] Te Whatu Ora Waitemata, Gen Surg Serv, Auckland, New Zealand
关键词
MAORI; MANAGEMENT; COMORBIDITY; DISPARITIES; IMPACT; STAGE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Maori are less likely to survive their lung cancer once diagnosed, but it remains unclear whether this is partially driven by poorer access to best-practice diagnostic services. Methods: We examined all lung cancer registrations in Aotearoa New Zealand between 2007-2019 (n=27,869) linked to national administrative health datasets and further stratified by ethnicity, tumour type and stage of disease. Using descriptive and regression analyses, we compared ethnic groups in terms of the basis of diagnosis (e.g., histology, cytology), receipt of bronchoscopy and travel distance and time to access bronchoscopy. Results: We found no differences in access to a pathological diagnosis between ethnic groups regardless of cancer type or stage. We found that M & amacr;ori within the cohort were marginally more likely to access bronchoscopy than the majority European group; however, we also found that M & amacr;ori had lower odds of living close to the location of their bronchoscopy, and correspondingly higher odds of living 100-200km (adjusted odds ratio [adj. OR] 1.46, 95% confidence interval [CI] 1.26-1.69) or more than 200km away (1.36, 95% CI 1.15-1.61) than Europeans. Conclusion: Interventions that aim to further support M & amacr;ori to overcome the systematic and cumulative disadvantages in access to cancer care should be broadly supported and resourced.
引用
收藏
页码:40 / 58
页数:19
相关论文
共 50 条
  • [41] Access to healthcare: Opioid substitution treatment following a disaster in Aotearoa New Zealand
    Blake, Denise
    AUSTRALIAN COMMUNITY PSYCHOLOGIST, 2018, 29 (01): : 121 - 138
  • [42] Abortion Services in Aotearoa New Zealand: The Voices of Wāhine on Improving Access
    Dallas-Katoa, W.
    Mgibson
    Slater, T.
    AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2025, 65
  • [43] Maori and cancer care in Aotearoa/New Zealand - responses to disparities
    Robson, B.
    Ellison-Loschmann, L.
    EUROPEAN JOURNAL OF CANCER CARE, 2016, 25 (02) : 214 - 218
  • [44] Patients' and carers' priorities for cancer research in Aotearoa/New Zealand
    de Vries, Millie
    Stewart, Tiria
    Ireton, Theona
    Keelan, Karen
    Jordan, Jennifer
    Robinson, Bridget A.
    Dachs, Gabi U.
    PLOS ONE, 2023, 18 (08):
  • [45] ETHNIC INEQUITIES IN PROSTATE CANCER CARE IN AOTEAROA NEW ZEALAND
    Toh, E. Ann
    White, J.
    Clarke, J.
    Hider, P.
    Mark, S.
    INTERNAL MEDICINE JOURNAL, 2024, 54 : 16 - 17
  • [46] Impact of COVID-19 control on lung, breast, and colorectal pathological cancer diagnoses. A comparison between the Netherlands, Aotearoa New Zealand, and Northern Ireland
    Helen Mitchell
    Jennifer Mclean
    Anna T Gavin
    Otto Visser
    Elinor Millar
    Tessa Luff
    Damien Bennett
    BMC Cancer, 23
  • [47] Aotearoa New Zealand Social Work rebooted: Open access and the intellectual commons
    Ballantyne, Neil
    Lowe, Simon
    AOTEAROA NEW ZEALAND SOCIAL WORK, 2016, 28 (01): : 1 - 4
  • [48] Impact of COVID-19 control on lung, breast, and colorectal pathological cancer diagnoses. A comparison between the Netherlands, Aotearoa New Zealand, and Northern Ireland
    Mitchell, Helen
    Mclean, Jennifer
    Gavin, Anna T.
    Visser, Otto
    Millar, Elinor
    Luff, Tessa
    Bennett, Damien
    BMC CANCER, 2023, 23 (01)
  • [49] Usage and equity of access to isotretinoin in New Zealand by deprivation and ethnicity
    Moodie, Peter
    Jaine, Richard
    Arnold, Jason
    Bignall, Mike
    Metcalfe, Scott
    Arroll, Bruce
    NEW ZEALAND MEDICAL JOURNAL, 2011, 124 (1346) : 34 - 43
  • [50] Improving early detection of colorectal cancer in Aotearoa New Zealand: how do the direct access criteria perform?
    John, Rhys A.
    Wang, Holly
    Sylevych, Valentyna
    Falvey, James D.
    NEW ZEALAND MEDICAL JOURNAL, 2022, 135 (1564) : 31 - 40